This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Dementia cannot be confirmed until a patient is deceased. Dementia is hard on the patient, and often harder on the family or caregivers. They estimate that the number of people aged 65 years and older is expected to increase from 35 million in 2000 to 71 million in 2030. million in 2030. million in 2000 to 19.5
IGC”) (NYSE American: IGC) announces today that it has completed Cohort 2 of its Phase 1 clinicaltrial on IGC’s tetrahydrocannabinol (“THC”)-based investigational new drug, IGC-AD1, intended to alleviate the symptoms of individuals suffering from Alzheimer’s disease. This Phase 1 trial is currently testing IGC-AD1 for safety.
Deletion Syndrome – Global Market Insights, Epidemiology and Forecast to 2030” report has been added to ResearchAndMarkets.com’s offering. deletion syndrome patient pool and forecasted trend for each seven major countries. DUBLIN–(BUSINESS WIRE)–The “22q11.2 Country-Wise Epidemiology.
According to the Lancet Commission, mental health disorders are on the rise in every country worldwide, and the resulting lost productivity will cost the global economy $16 trillion by 2030. Despite the high prevalence of these disorders, few patients are accurately screened and diagnosed. of patients with social anxiety disorder.
DUBLIN–(BUSINESS WIRE)–The “Global Cannabis Market- Market Size & Forecast to 2030” report has been added to ResearchAndMarkets.com’s offering. million by 2030 at a CAGR of 23.9%, 2021-2030. ClinicalTrials of Cannabis Are Still on Going. German Narcotics Act. Narcotics Act (No.8)
DUBLIN–(BUSINESS WIRE)–The “Skin Cancer Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030” report has been added to ResearchAndMarkets.com’s offering. The global skin cancer drugs market is expected to grow from $1.44 billion in 2020 to $1.61
billion by 2030, growing at a CAGR of 8.4% from 2021 to 2030. Genomics test results allow practitioners and patients to set individualized, trackable goals around pharmacogenomics (PGx), cannabis DNA, nutrition DNA, and fitness DNA for personalized health and wellness. billion (2020).
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content